Literature DB >> 25952404

Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.

Moonyoung Chung1, Young Seok Park2, Ji Seon Kim3, Yun Joong Kim4, Hyeo Il Ma4, Su Jin Jang5, Ryoong Huh1, Hyun Sook Kim6, Won-Chan Kim6.   

Abstract

PURPOSE: To investigate the correlation between the striatal three-dimensional location and the Unified Parkinson's Disease Rating Scale (UPDRS) motor score in the context of idiopathic Parkinson's disease (PD) through radiolabeled N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane positron emission tomography/computed tomography (FP-CIT PET/CT).
MATERIALS AND METHODS: In this cross-sectional study, we assessed the UPDRS motor score and performed FP-CIT PET/CT in patients with PD. Thirty-eight patients with idiopathic PD [average 70 years of age (range 49-86); male:female ratio 12:26] were enrolled. The correlation between FP-CIT PET/CT and the UPDRS III scores was investigated after the transformation of PET images by an alternative method using MATLAB.
RESULTS: Left caudate nucleus uptake negatively correlated with UPDRS items 18, 20 (face), 22 (right arm and leg), 23, 24 (right side), 26 (right side), 27, 30, and 31, while right caudate nucleus uptake positively correlated with items 18, 22 (left arm), 26, and 29. Putamen uptake correlated with items 22 and 25. Left caudate nucleus uptake positively correlated with axial and akinetic-rigidity symptoms.
CONCLUSIONS: FP-CIT uptake in specific basal ganglia structures strongly correlated with the UPDRS III motor score. Among these, the left caudate nucleus exhibited the strongest relationship with axial and akinetic-rigidity PD symptoms.

Entities:  

Keywords:  Iodine-123 fluoropropyl–carbomethoxy-3β-(4-iodophenyl) nortropane; PET; Parkinson’s disease; Three-dimensional analysis; UPDRS

Mesh:

Substances:

Year:  2015        PMID: 25952404     DOI: 10.1007/s11604-015-0427-0

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  25 in total

1.  Progression of parkinsonian signs in Parkinson disease.

Authors:  E D Louis; M X Tang; L Cote; B Alfaro; H Mejia; K Marder
Journal:  Arch Neurol       Date:  1999-03

2.  Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies.

Authors:  Nikolaos Papathanasiou; Phivi Rondogianni; Panagiota Chroni; Marios Themistocleous; Efstathios Boviatsis; Xanthi Pedeli; Damianos Sakas; Ioannis Datseris
Journal:  Ann Nucl Med       Date:  2012-01-12       Impact factor: 2.668

3.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

4.  Functional decline in Parkinson disease.

Authors:  J Jankovic; A S Kapadia
Journal:  Arch Neurol       Date:  2001-10

5.  Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Authors:  H T Benamer; J Patterson; D J Wyper; D M Hadley; G J Macphee; D G Grosset
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

6.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

Authors:  F J Vingerhoets; M Schulzer; D B Calne; B J Snow
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

7.  Course in Parkinson disease subtypes: A 39-year clinicopathologic study.

Authors:  A H Rajput; A Voll; M L Rajput; C A Robinson; A Rajput
Journal:  Neurology       Date:  2009-07-21       Impact factor: 9.910

8.  Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study.

Authors:  Y Ma; V Dhawan; M Mentis; T Chaly; P G Spetsieris; D Eidelberg
Journal:  Synapse       Date:  2002-08       Impact factor: 2.562

9.  Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients.

Authors:  Valentina Berti; Alberto Pupi; Silvia Ramat; Eleonora Vanzi; Maria Teresa De Cristofaro; Giannantonio Pellicanò; Francesco Mungai; Paolo Marini; Sandro Sorbi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-23       Impact factor: 9.236

Review 10.  Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?

Authors:  Rick C Helmich; Mark Hallett; Günther Deuschl; Ivan Toni; Bastiaan R Bloem
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

View more
  5 in total

Review 1.  PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan.

Authors:  Tomohiro Kaneta
Journal:  Jpn J Radiol       Date:  2020-02-10       Impact factor: 2.374

2.  Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer.

Authors:  Li Jun Zuo; Shu Yang Yu; Fang Wang; Yang Hu; Ying Shan Piao; Yang Du; Teng Hong Lian; Rui Dan Wang; Qiu Jin Yu; Ya Jie Wang; Xiao Min Wang; Piu Chan; Sheng Di Chen; Yongjun Wang; Wei Zhang
Journal:  J Clin Neurol       Date:  2016-02-04       Impact factor: 3.077

3.  18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease.

Authors:  YoungSoon Yang; Miju Cheon; Yong Tae Kwak
Journal:  Dement Neurocogn Disord       Date:  2017-09-30

4.  Brain iron deposition is linked with cognitive severity in Parkinson's disease.

Authors:  George Edward Calver Thomas; Louise Ann Leyland; Anette-Eleonore Schrag; Andrew John Lees; Julio Acosta-Cabronero; Rimona Sharon Weil
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-02-20       Impact factor: 10.154

Review 5.  LRRK2 at the Crossroad of Aging and Parkinson's Disease.

Authors:  Eun-Mi Hur; Byoung Dae Lee
Journal:  Genes (Basel)       Date:  2021-03-29       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.